About Octagon Capital Advisors
Octagon Capital Advisors is a venture capital firm founded in 2019. It is primarily based out of New York City, United States. As of Aug 2026, Octagon Capital Advisors is an active investor, having invested in 42 companies, with 2 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Obsidian Therapeutics Overall, Octagon Capital Advisors portfolio has seen 19 IPOs and 6 acquisitions including key companies like Forge Biologics, Century Therapeutics and 4D Molecular Therapeutics. A lot of funds co-invest with Octagon Capital Advisors, with names like RA Capital Management sharing a substantial percentage of its portfolio. Octagon Capital Advisors has team of 6 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Octagon Capital Advisors' List of Top Investments
Octagon Capital Advisors has a portfolio of 42 companies. Their most notable investments are in Vedere and Aktis Oncology.Their portfolio spans across United States, China, Singapore and 1 more locations. They have invested in Life Sciences, High Tech, HealthTech and 1 other sectors, across stages such as Series B, Series C and 3 more. Here is the list of top investments by Octagon Capital Advisors:
Developer of gene therapeutic solutions for treating multiple diseases. It has developed gene therapies that aim to help patients suffering from rare diseases. Products include FBX-101 which helps to treat infantile Krabbe diseases, FBX-201 for rare and monogenic diseases, and FBX-301 for rare & cancer diseases.
Key facts about Forge Biologics
- Founded Year: 2020
- Location: Columbus (United States)
- Stage: Acquired
- Total Funding till date: $330M
- Employee Count: 438 as on Aug 31, 2026
- Investors: Perceptive Advisors, Marshall Wace and 7 Others
- Latest Funding Round: Series C, Sep 12, 2022, $*****
- Highlight: Acquired
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
Key facts about Century Therapeutics
- Founded Year: 2018
- Location: Philadelphia (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $410M
- Employee Count: 119 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Venrock and 22 Others
- Latest Funding Round: Post IPO, Jan 08, 2026, $*****
- Highlight: Public
4d Molecular Therapeutics researchers develop gene therapy products for severe genetic diseases involving a diverse array of target tissues, including the following areas: retina, heart, liver, brain (CNS), skeletal muscle, and lung. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body.
Key facts about 4D Molecular Therapeutics
- Founded Year: 2013
- Location: Emeryville (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $187M
- Employee Count: 221 as on Sep 30, 2026
- Investors: BVF Partners, ArrowMark Partners and 18 Others
- Latest Funding Round: Series C, Jun 16, 2020, $*****
- Highlight: Public
_1548143983431.png?format=webp&height=120&width=120){kind=logo}
Beijing Jiakesi is developing small molecule-based therapeutics for cancer treatment. The company's lead product candidate JAB-3068 is an anti-tumor small molecule which is in Phase 1 clinical trials. Other products of the company include JAB-3000, JAB-6000, JAB-8000 used against cancer which are in pre-clinical trials.
Key facts about Beijing Jiakesi drug development
- Founded Year: 2015
- Location: Beijing (China)
- Stage: Public
- Total Funding till date: $55M
- Employee Count: 43 as on Aug 31, 2026
- Investors: Hillhouse, Octagon Capital Advisors and 3 Others
- Latest Funding Round: Series C, Aug 30, 2018, $*****
- Highlight: Public
Developer of antibody therapeutics in immunology and oncology disease. The products Batoclimab for the treatment of autoimmune diseases, Tanfanercept for the treatment of dry eye disease, HBM4003, HBM9022, to prevent and treat COVID-19, and various candidates for treating solid tumors, myeloma, and cancer. The company has a Harbour Mice, HBICE, and single-cell technology platform to generate fully human monoclonal antibodies.
Key facts about Harbour BioMed
- Founded Year: 2016
- Location: Shanghai (China)
- Stage: Public
- Total Funding till date: $313M
- Employee Count: 113 as on Sep 30, 2026
- Investors: Atlas Venture, GIC and 19 Others
- Latest Funding Round: Series C, Jul 09, 2020, $*****
- Highlight: Public
Octagon Capital Advisors' Year-on-Year Investment Trends
Octagon Capital Advisors has invested in 42 companies over the last 6 years, with an average of 2 new investments annually in the last 5 years. In 2025, it made 1 investment, while as of Aug 2026, it has made 2 investments in this year. Its most recent first time investment was in Obsidian Therapeutics and most recent follow-on round was in Numab.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 2 | 0 | 2 |
2025 | 0 | 1 | 1 |
2024 | 3 | 2 | 5 |
2023 | 0 | 1 | 1 |
2022 | 2 | 1 | 3 |
2021 | 18 | 2 | 20 |
2020 | 7 | 0 | 7 |
Octagon Capital Advisors' Investments by Stage
Octagon Capital Advisors has made 13 investments in Series B stage with an average round size of $86.3M, 10 investments in Series C stage with an average round size of $148M, 5 investments in Series A stage with an average round size of $51.8M, 3 investments in Post IPO stage with an average round size of $167M and 1 investment in Series D stage.Stage of entry | No. of Investments |
|---|---|
Series B | 13 |
Series C | 10 |
Series A | 5 |
Post IPO | 3 |
Series D | 1 |
Note: We have considered here, only first round of investments
Octagon Capital Advisors' Investments by Sector
Octagon Capital Advisors has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Healthcare and Robotics - Industry Applications. Notably, it has invested in 38 Tech companies, 36 Enterprise (B2B) companies, 4 Tech hardware companies and at least 1 company focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 30 |
High Tech | 6 |
Sustainability Tech | 3 |
Healthcare | 1 |
Robotics - Industry Applications | 1 |
Note: We have considered here, only first round of investments
Octagon Capital Advisors' Investments by Geography
Octagon Capital Advisors has made most investments in United States (21), followed by China where it has made 9 investments.Country | No. of Investments |
|---|---|
United States | 21 |
China | 9 |
Singapore | 1 |
Switzerland | 1 |
Note: We have considered here, only first round of investments
Octagon Capital Advisors' recent investments
Octagon Capital Advisors has made 2 investments in 2026 so far - Obsidian Therapeutics and Epicrispr Bio.Here are the most recent investments by Octagon Capital Advisors:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Aug 05, 2026 | United States | Post IPO | 5213 | ||
May 04, 2026 | United States | Series C | 6070 | ||
Jan 09, 2025 | Switzerland | Series C | 2954 | ||
May 01, 2024 | United States | Series C | 8016 | ||
Apr 11, 2024 | United States | Post IPO | 4673 |
IPOs and Publicly Listed companies in Octagon Capital Advisors' Portfolio
19 of Octagon Capital Advisors' portfolio companies have become public. Obsidian Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 and Alebund got listed on the Hong Kong Exchanges (HKG) at marketcap of $979M.Here are Octagon Capital Advisors' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 04, 2026 | Aug 05, 2026 | Post IPO | 1357 | |
Jun 29, 2026 | Sep 13, 2021 | Series B | 4787 | |
Jan 09, 2026 | Mar 18, 2021 | Series A | 9813 | |
Jan 08, 2026 | Nov 08, 2021 | Series C | 4859 | |
Jan 26, 2024 | Dec 16, 2022 | Series B | 9309 |
Acquired companies in Octagon Capital Advisors' Portfolio
6 companies from Octagon Capital Advisors' portfolio have been acquired. The most recent acquisition was Cullgen in Mar 2026 by Gyre Therapeutics for $*****.Here are Octagon Capital Advisors' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 02, 2026 | Feb 25, 2021 | Series B | 8776 | |
Dec 08, 2025 | Aug 16, 2022 | Series B | 2592 | |
Apr 30, 2025 | Mar 12, 2024 | Post IPO | 2127 | |
Apr 03, 2024 | Feb 13, 2024 | Series B | 4819 | |
Nov 13, 2023 | Apr 28, 2021 | Series B | 7982 |
Team profile of Octagon Capital Advisors
Octagon Capital Advisors has a team of 6 members including 1 Partner and 2 Principals located in United States. Octagon Capital Advisors' team does not sit on the board of any company as of now.Here is a list of all team members in Octagon Capital Advisors:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | New York City | - | - | |
Principal | New York City | - | - | |
Principal | New York City | - | - |
Co-investors of Octagon Capital Advisors
Over the past 6 years, 361 investors have co-invested in Octagon Capital Advisors's portfolio companies. This includes funds and angels.
- Invested before Octagon Capital Advisors: Atlas Venture, Decheng Capital and 131 others have invested in rounds before Octagon Capital Advisors. There are 3 companies where Atlas Venture has invested before Octagon Capital Advisors and 3 companies where Decheng Capital has invested before Octagon Capital Advisors.
- Top Co-investors of Octagon Capital Advisors: 157 investors entered a company along with Octagon Capital Advisors. These include investors like RA Capital Management (6 companies).
- Invested after Octagon Capital Advisors: A total of 71 investors have invested in Octagon Capital Advisors's portfolio after their investments. Top Investors include RA Capital Management (4 companies), TCG Crossover (3 companies) and RTW Investments (3 companies).
Recent News related to Octagon Capital Advisors
•
•
Octagon Capital Advisors LP Invests $13.77 Million in Tourmaline Bio, Inc. $TRMLMarketBeat•Sep 11, 2025•Tourmaline Bio, Octagon Capital Advisors
•
Taysha Gene Therapies, Inc. $TSHA Shares Acquired by Octagon Capital Advisors LPMarketBeat•Sep 11, 2025•Octagon Capital Advisors, Taysha Gene Therapies
•
Octagon Capital Advisors LP Invests $10.37 Million in Verastem, Inc. $VSTMMarketBeat•Sep 11, 2025•Octagon Capital Advisors, Verastem
•
Octagon Capital Advisors LP Acquires Shares of 296,000 MoonLake Immunotherapeutics $MLTXMarketBeat•Sep 11, 2025•MoonLake, Octagon Capital Advisors
•
Octagon Capital Advisors LP Raises Stake in aTyr Pharma, Inc. $ATYRMarketBeat•Sep 11, 2025•Octagon Capital Advisors, aTyr Pharma
•
Octagon Capital Makes New $20.90 Million Investment in Trevi TherapeuticsMarketBeat•Sep 11, 2025•Octagon Capital Advisors, Trevi Therapeutics
•
Octagon Capital Advisors LP Acquires New Holdings in Apogee Therapeutics Inc. $APGEMarketBeat•Sep 11, 2025•Apogee Therapeutics, Octagon Capital Advisors
•
Octagon Capital Advisors Acquires KalVista Pharmaceuticals StockMarketBeat•May 15, 2025•Octagon Capital Advisors, KalVista
•
Octagon Capital Advisors LP Increases Regulus Therapeutics StakeMarketBeat•May 15, 2025•Octagon Capital Advisors, Regulus Therapeutics
